"MIRO" Molecularly Oriented Immuno-radio-therapy
NCT02710643
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
110
Enrollment
OTHER
Sponsor class
Conditions
Follicular Lymphoma, Grade 1
Follicular Lymphoma, Grade 2
Follicular Lymphoma Grade 3A
Interventions
DRUG:
OFATUMUMAB
Sponsor
Fondazione Italiana Linfomi - ETS